Page 136 - MEMORIA ANUAL 2019 SEHH-FEHH

MEMORIA ANUAL 2019
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
Alcoceba M, González M, Colado E, Ramírez Payer A, Capdevila C, Osuna M, Ayme- rich M, Mares R, López-Guerra M, Magnano L, Mozas P, Rivas-Delgado A, Terol MJ, Enjuanes A, Huber W, López-Guillermo A, Beà S, Martín-Subero JI, Zenz T, Taylor MD, Colomer D, Puente XS, Stein LD, Campo E. The U1 Spliceosomal RNA: a Nov- el Non-Coding Hotspot Driver Mutation Independently Associated with Clinical Outcome in Chronic Lymphocytic Leukemia. 61st American Society of Hematology (ASH) Annual Meeting. Orlando, Florida, December 2019.
• Abrisqueta P, González-Barca E, Ferra CM, Ríos Herranz E, Fernández M, Delgado J, Andreu R, Hernández-Rivas JA, Terol MJ, González M, Baltasar Tello P, de la Serna J, Ra- mírez Payer A, Ballester C, Moreno C, García-Marco JA, Córdoba R, Yáñez San Segundo L, Casado Montero LF, Bosch F. Preliminary Results of Ibrutinib Followed By Ofatu- mumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC). 61st Ameri- can Society of Hematology (ASH) Annual Meeting. Orlando, Florida, December 2019.
• Ferra CM, Pérez Encinas M, López Jiménez J, Ortiz M, Osorio-Prendes S, Córdoba R, Ramírez Payer A, González-Barca E, Martín Sánchez G, González Díaz M, Sánchez MJ, Fernández M, Baltasar Tello P, Amutio E, García-Malo MD, Vidal Maceñido MJ, Fernández P, Loscertales J, Rodríguez JN, Aláez C, Ramroth H, Palla M. Retrospec- tive Non-Interventional Assessment of the Use of Idelalisib in Relapsed/Refrac- tory Chronic Lymphocytic Leukemia Patients in Spain. 61st American Society of Hematology (ASH) Annual Meeting. Orlando, Florida, December 2019.
• Loscertales J, Delgado J, Oliveira AC, Martín Rodríguez L, Ferra Coll C, Ramírez-Pa- yer A, Hernández JA, Vidal Mancenido MJ, Muntanola Prat A, Bárez García A, Medina Pérez MA, Rubio-Martínez A, Collado R, Más-Ochoa MC, Mascaró Riera M, Navarro A, Romero Fernández P, Sanz-García A, Bosch F. Real-life retrospective compari- son of chlorambucil plus anti-CD20 antibody versus ibrutinib alone as frontline treatment for unfit CLL/SLL. XVIII International Workshop on Chronic Lymphocytic Leukemia (iwCLL). Edinburgh, September 2019.
• González-Gascón y Marín I, Figueroa I, Munoz C, Infante MS, Foncillas MA, Marín K, Churruca J, Hernández Sánchez M, Rodríguez-Vicente AE, González Díaz MG, Hernández Rivas JM, Hernández Rivas JA. 2067. Trisomy 12 worsens the outcome of early-stage CLL patients with mutated IGHV genes and 11q deletion of the patients with unmutated IGHV genes. XVIII iwCLL. Edinburgh, September 2019.
GRUPO ESPAñOL DE LEUCEMIA LINFOCÍTICA CRóNICA (GELLC)
136